The Journal of nutrition · 2025
Bilberry (Vaccinium myrtillus L.) Peel-Enriched Pomace as Natural Anticancer Agents: Preclinical Evidence from Breast Carcinoma Models Supporting Preventive and Personalized Treatment Strategies.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dvorska Dana, Zilakova Simona, Medvecova Viktoria, Sebova Dominika, Kajo Karol, Baranovicova Eva, Vanekova Zuzana, Goga Michal, Routray Deepti, Strnadel Jan, Baranova Ivana, Halasova Erika, Dankova Zuzana, Brozmanova Mariana, Hornak Slavomir, Sadlonova Vladimira, Novakova Elena, Rollinger Judith M, Cizkova Dasa, Golubnitschaja Olga, Brany Dusan, Kello Martin, Kubatka Peter
Аннотация
BACKGROUND: Breast cancer (BC) is the most commonly diagnosed malignancy in women (∼25% of new cases). Plants adapted to specific niches accumulate secondary metabolites with bioactivity, including anticancer effects.
OBJECTIVE: The objective of this study was to evaluate the chemopreventive and treatment potential of Vaccinium myrtillus (bilberry) peel-enriched pomace powder in BC models, hypothesizing system-level effects and synergy with standard therapy.
METHODS: Chemistry was profiled by liquid chromatography with diode-array detection-mass spectrometry (LC-DAD-MS)/liquid chromatography with diode-array detection (LC-DAD) from 2 extracts: BILHEX (hexane) and BILMeOH (methanol). Biology was tested in the following: 1) 4T1 triple-negative mouse model (treatment); 2) NMU rat mammary carcinogenesis (chemoprevention); and 3) in vitro assays with MCF-7 and MDA-MB-231, including 3D spheroids and cisplatin combinations.
RESULTS: BILMeOH was enriched for phenolics; BILHEX for unsaturated triacylglycerols/triterpene acids. Compared with control, bilberry diet reduced 4T1 tumor volume by 51% and 91% (low/high dose; P < 0.05/0.001), lowered mitotic index (P < 0.001), and reduced necrosis:tumor ratio (P < 0.05). In NMU rats, chemoprevention increased cleaved caspase-3 (P < 0.05) and Bax/Bcl-2 (P < 0.001), and decreased Ki-67 (P < 0.05), MDA, and CD133 (P < 0.01). Histone marks shifted (↓H3K4me3 P < 0.05; ↑H4K20me3 P < 0.01; ↑H4K16ac P < 0.001). Promoter methylation was gene-specific (e.g., RASSF1 +12% absolute, P < 0.05); low-baseline loci were treated as low magnitude. miRNA profiling (758 features) identified significant dysregulation (|FC| ≥ 2) of let-7d-5p, let-7i-5p, miR-1224-3p, miR-494-3p, and miR-6216. TGF-β and IL-10 increased (both P < 0.001), IL-6 rose (P < 0.05), indicating selective immunomodulation. Metabolomics showed shifts in lactate (P < 0.05), branched-chain ketoacids (P < 0.05/0.01), and histidine (P < 0.001). In vitro, BILHEX suppressed proliferation, induced G2/M arrest, activated intrinsic apoptosis (cytochrome-c → caspase-9 → caspase-3/7 → PARP), and synergized with cisplatin in 3D spheroids (Bliss).
CONCLUSIONS: Bilberry pomace shows multitarget anticancer activity across BC models; translational studies should confirm mechanisms, refine dosing, and explore biomarker-guided use.
OBJECTIVE: The objective of this study was to evaluate the chemopreventive and treatment potential of Vaccinium myrtillus (bilberry) peel-enriched pomace powder in BC models, hypothesizing system-level effects and synergy with standard therapy.
METHODS: Chemistry was profiled by liquid chromatography with diode-array detection-mass spectrometry (LC-DAD-MS)/liquid chromatography with diode-array detection (LC-DAD) from 2 extracts: BILHEX (hexane) and BILMeOH (methanol). Biology was tested in the following: 1) 4T1 triple-negative mouse model (treatment); 2) NMU rat mammary carcinogenesis (chemoprevention); and 3) in vitro assays with MCF-7 and MDA-MB-231, including 3D spheroids and cisplatin combinations.
RESULTS: BILMeOH was enriched for phenolics; BILHEX for unsaturated triacylglycerols/triterpene acids. Compared with control, bilberry diet reduced 4T1 tumor volume by 51% and 91% (low/high dose; P < 0.05/0.001), lowered mitotic index (P < 0.001), and reduced necrosis:tumor ratio (P < 0.05). In NMU rats, chemoprevention increased cleaved caspase-3 (P < 0.05) and Bax/Bcl-2 (P < 0.001), and decreased Ki-67 (P < 0.05), MDA, and CD133 (P < 0.01). Histone marks shifted (↓H3K4me3 P < 0.05; ↑H4K20me3 P < 0.01; ↑H4K16ac P < 0.001). Promoter methylation was gene-specific (e.g., RASSF1 +12% absolute, P < 0.05); low-baseline loci were treated as low magnitude. miRNA profiling (758 features) identified significant dysregulation (|FC| ≥ 2) of let-7d-5p, let-7i-5p, miR-1224-3p, miR-494-3p, and miR-6216. TGF-β and IL-10 increased (both P < 0.001), IL-6 rose (P < 0.05), indicating selective immunomodulation. Metabolomics showed shifts in lactate (P < 0.05), branched-chain ketoacids (P < 0.05/0.01), and histidine (P < 0.001). In vitro, BILHEX suppressed proliferation, induced G2/M arrest, activated intrinsic apoptosis (cytochrome-c → caspase-9 → caspase-3/7 → PARP), and synergized with cisplatin in 3D spheroids (Bliss).
CONCLUSIONS: Bilberry pomace shows multitarget anticancer activity across BC models; translational studies should confirm mechanisms, refine dosing, and explore biomarker-guided use.